[Comparison of SAPS II, MPM II24 and SAPS in intensive care].

Objective: To compare the performance of the new SAPS II, new MPM2 and SAPS in a cohort of patients admitted to our polyvalent ICU.

Design: the ability of the SAPS II scoring system to predict the probability of hospital mortality was assessing calibration and discrimination (ROC curve) measures obtained using published coefficients and within relevant subgroups using formal statistic assessment (goodness of fit).

Patients: from May 1997 to May 1998, 420 consecutive patients over 18 years old.

Intractable epilepsies. An open trial with Clobazam.

Clobazam was used as an added treatment in 28 patients with intractable epilepsies: 26 subjects had associated handicaps. A good response was observed during the first two-three months of Clobazam treatment: the reduction in seizure frequency of 73% for partial seizures and 62% for GTCs. A tolerance to Clobazam treatment was observed after the third month of treatment: at the end of the sixth month, the seizure frequency was reduced to 36% for partial seizures and 39% for GTCs.